Free Trial
NASDAQ:HOOK

HOOKIPA Pharma (HOOK) Stock Price, News & Analysis

HOOKIPA Pharma logo
$1.23 +0.02 (+1.65%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.23 0.00 (0.00%)
As of 08:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About HOOKIPA Pharma Stock (NASDAQ:HOOK)

Key Stats

Today's Range
$1.19
$1.25
50-Day Range
$1.18
$1.75
52-Week Range
$0.72
$6.77
Volume
20,378 shs
Average Volume
81,659 shs
Market Capitalization
$14.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Hold

Company Overview

HOOKIPA Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

HOOK MarketRank™: 

HOOKIPA Pharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 412th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    HOOKIPA Pharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    HOOKIPA Pharma has received no research coverage in the past 90 days.

  • Read more about HOOKIPA Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for HOOKIPA Pharma are expected to decrease in the coming year, from ($1.75) to ($2.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of HOOKIPA Pharma is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of HOOKIPA Pharma is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    HOOKIPA Pharma has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about HOOKIPA Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    1.87% of the float of HOOKIPA Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    HOOKIPA Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in HOOKIPA Pharma has recently decreased by 25.24%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    HOOKIPA Pharma does not currently pay a dividend.

  • Dividend Growth

    HOOKIPA Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.87% of the float of HOOKIPA Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    HOOKIPA Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in HOOKIPA Pharma has recently decreased by 25.24%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for HOOKIPA Pharma this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, HOOKIPA Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.30% of the stock of HOOKIPA Pharma is held by insiders.

  • Percentage Held by Institutions

    63.88% of the stock of HOOKIPA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about HOOKIPA Pharma's insider trading history.
Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HOOKIPA Pharma and its competitors with MarketBeat's FREE daily newsletter.

HOOK Stock News Headlines

Hookipa Pharma Inc News (HOOK) - Investing.com
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Hookipa Pharma (HOOK) Receives a Hold from RBC Capital
Hookipa Pharma Drops Poolbeg Takeover Bid
See More Headlines

HOOK Stock Analysis - Frequently Asked Questions

HOOKIPA Pharma's stock was trading at $2.01 at the beginning of the year. Since then, HOOK stock has decreased by 38.8% and is now trading at $1.23.

HOOKIPA Pharma Inc. (NASDAQ:HOOK) released its quarterly earnings results on Thursday, May, 15th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.62. HOOKIPA Pharma had a negative trailing twelve-month return on equity of 120.09% and a negative net margin of 785.66%.

Shares of HOOKIPA Pharma reverse split on Wednesday, July 10th 2024.The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

HOOKIPA Pharma (HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that HOOKIPA Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Pfizer (PFE), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
5/15/2025
Today
7/11/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HOOK
CIK
1760542
Employees
160
Year Founded
N/A

Price Target and Rating

High Price Target
$7.00
Low Price Target
$2.00
Potential Upside/Downside
+265.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.50 million
Net Margins
-785.66%
Pretax Margin
-785.15%
Return on Equity
-120.09%
Return on Assets
-77.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.61
Quick Ratio
3.61

Sales & Book Value

Annual Sales
$43.95 million
Price / Sales
0.34
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.25 per share
Price / Book
0.29

Miscellaneous

Outstanding Shares
12,190,000
Free Float
11,787,000
Market Cap
$14.99 million
Optionable
Optionable
Beta
0.89
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:HOOK) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners